Mood disorders are associated with a more severe hypovitaminosis D than schizophrenia

被引：29

作者：

Belzeaux, Raoul ^{[1
,2
,3
]}

Boyer, Laurent ^{[4
]}

Ibrahim, El Cherif ^{[2
,3
]}

Feron, Francois ^{[5
]}

Leboyer, Marion ^{[3
,6
]}

Fond, Guillaume ^{[3
,6
]}

机构：

[1] La Concept Univ Hosp, Sainte Marguerite Univ Hosp, Assistance Publ Hop Marseille, Dept Psychiat, Marseille, France

[2] Aix Marseille Univ, CNRS, CRN2M, UMR 7286, Marseille, France

[3] Fdn Cooperat Sci Sante Mentale, Fdn FondaMental, Creteil, France

[4] La Timone Univ Hosp, Assistance Publ Hop Marseille, Dept Publ Hlth, EA Res Unit 3279, Marseille, France

[5] Aix Marseille Univ, CNRS, NICN, UMR7259, F-13344 Marseille, France

[6] Univ Paris Est Creteil, GHU Mondor, DHU Pe Psy, INSERM,U955, Creteil, France

来源：

PSYCHIATRY RESEARCH | 2015年 / 229卷 / 1-2期

关键词：

Vitamin D; Major depression; Bipolar disorders; Dysthymia; Schizophrenia; VITAMIN-D DEFICIENCY; METAANALYSIS; DEPRESSION; HEALTH;

D O I：

10.1016/j.psychres.2015.04.039

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Patients with psychiatric disorders display high levels of hypovitaminosis D (< 50 nmol/L). It remains unclear whether it is associated with specific diagnoses. To further explore vitamin D status in psychiatric inpatients, 82 individuals with mood disorders or schizophrenia/schizoaffective disorders were included. Hypovitaminosis D was significantly lower in patients with mood disorders than patients with schizophrenia (standardized beta coefficient=0.385, p = 0.007). Further studies are warranted to determine specific causes of hypovitaminosis D and the interest of supplementation. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：613 / 616

页数：4

共 50 条

[41] Is hypovitaminosis D a consequence rather than cause of disease?
Shee, Charles
THORAX, 2013, 68 (07) : 679 - 679
[42] Role of Vitamin D as Adjuvant Therapy of Hypovitaminosis D in Patients of Schizophrenia
Malik, Bilal Rafique
Zafar, Muhammad Hassan
Khan, Samiullah
PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2019, 13 (01): : 303 - 305
[43] Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal, John H.
Tolin, David F.
Sanacora, Gerard
Castner, Stacy A.
Williams, Graham V.
Aikins, Deane E.
Hoffman, Ralph E.
D'Souza, D. Cyril
DRUG DISCOVERY TODAY, 2009, 14 (13-14) : 690 - 697
[44] Mitochondrial gene expression in mood disorders and schizophrenia
Shao, Ling
Choudary, Prabhakara
Li, Jun
Evans, Simon
Myers, Rick
Jones, Edward G.
Watson, Stanley J.
Akil, Huda
Bunney, William
Vawter, Marquis
BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 157S - 157S
[45] Catatonia in inpatients with psychiatric disorders: A comparison of schizophrenia and mood disorders
Grover, Sandeep
Chakrabarti, Subho
Ghormode, Deepak
Agarwal, Munish
Sharma, Akhilesh
Avasthi, Ajit
PSYCHIATRY RESEARCH, 2015, 229 (03) : 919 - 925
[46] Race and hospital diagnoses of schizophrenia and mood disorders
Barnes, Arnold
SOCIAL WORK, 2008, 53 (01) : 77 - 83
[47] The pathomorphology of schizophrenia and mood disorders: similarities and differences
Baumann, B
Bogerts, B
SCHIZOPHRENIA RESEARCH, 1999, 39 (02) : 141 - 148
[48] Neurocognition as a stable endophenotype in mood disorders and schizophrenia
Goldberg, JF
Burdick, KE
Malhotra, AK
Harrow, M
BIOLOGICAL PSYCHIATRY, 2004, 55 : 91S - 92S
[49] MINOR PHYSICAL ANOMALIES IN SCHIZOPHRENIA AND MOOD DISORDERS
LOHR, JB
FLYNN, K
SCHIZOPHRENIA BULLETIN, 1993, 19 (03) : 551 - 556
[50] The role of aripiprazole in the treatment of schizophrenia and mood disorders
Gorostowicz, Aleksandra
Siwek, Marcin
PSYCHIATRIA I PSYCHOLOGIA KLINICZNA-JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY, 2018, 18 (03): : 296 - 305

← 1 2 3 4 5 →